FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1317-1321 May 6, 1993 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

An increased risk of lymphoproliferative disorders has been well documented in patients who are treated with immunosuppressive agents after organ transplantation¹ and in patients with the acquired immunodeficiency syndrome². The lymphomas that develop in immunosuppressed patients after transplantation are typically large-cell lymphomas that contain Epstein-Barr virus (EBV) and are closely linked to the level of competence of the immune system³. When treatment with immunosuppressive drugs is reduced or discontinued, these EBV-associated lymphomas may regress completely¹; if the patient's immune status continues to be compromised, however, the tumor may continue to proliferate and result in death.

Whether patients . . . [Full Text of this Article]

Case Reports

Patient 1

Patient 2

Methods

Histologic and Immunohistochemical Studies

Studies of In Situ Hybridization

Results

Patient 1

Patient 2

Discussion

Source Information

From the Department of Pathology, Stanford University Medical Center, Stanford, Calif. (O.W.K., M.R., R.A.W., R.F.D.); the Department of Pathology, City of Hope National Medical Center, Duarte, Calif. (L.M.W.); the Department of Molecular and Experimental Medicine and Division of Hematology/Medical Oncology (G.J.D.Z.), the Division of Rheumatology (P.K.H.), and the Department of Pathology (B.A.R.), Scripps Clinic and Research Foundation, La Jolla, Calif.; and the Division of Hematology/Oncology, Mountain States Tumor Institute, Boise, Idaho (P.G.M.).

Address reprint requests to Dr. Kamel at the Department of Pathology, Stanford University Medical Center, 300 Pasteur Dr., Stanford, CA 94305.

References

Related Letters:

Reversible Lymphomas
Shiroky J. B., Newkirk M. M., Kamel O. W., van de Rijn M., Warnke R. A., Dorfman R. F.
Extract | Full Text  
N Engl J Med 1993; 329:1657-1658, Nov 25, 1993. Correspondence

Cyclosporine and Methotrexate for Severe Rheumatoid Arthritis
Schlesinger N., Huppert A., Hoch S., Malleson P., Steinberg A. D., Rosh J. R., Birnbaum A. H., van de Rijn M., Kamel O. W., Storb R., Thomas E. D., Tugwell P., Yocum D., Pincus T., Wells G.
Extract | Full Text  
N Engl J Med 1995; 333:1567-1569, Dec 7, 1995. Correspondence

This article has been cited by other articles:

• Evans, S. J., Watson, D. K., O'Sullivan, M. (2008). Reversible Hodgkin's lymphoma associated with Epstein-Barr virus occurring during azathioprine therapy for SLE. Rheumatology (Oxford) 47: 1103-1104 [Full Text]  
• (2008). ANSWERS. Br. J. Ophthalmol. 92: 855-855 [Full Text]  
• Biggar, R. J., Jaffe, E. S., Goedert, J. J., Chaturvedi, A., Pfeiffer, R., Engels, E. A., for the HIV/AIDS Cancer Match Study, (2006). Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108: 3786-3791 [Abstract] [Full Text]  
• Smedby, K. E., Baecklund, E., Askling, J. (2006). Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics.. Cancer Epidemiol. Biomarkers Prev. 15: 2069-2077 [Abstract] [Full Text]  
• Franklin, J, Lunt, M, Bunn, D, Symmons, D, Silman, A (2006). Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 65: 617-622 [Abstract] [Full Text]  
• Engels, E. A., Cerhan, J. R., Linet, M. S., Cozen, W., Colt, J. S., Davis, S., Gridley, G., Severson, R. K., Hartge, P. (2005). Immune-Related Conditions and Immune-Modulating Medications as Risk Factors for Non-Hodgkin's Lymphoma: A Case-Control Study. Am J Epidemiol 162: 1153-1161 [Abstract] [Full Text]  
• Zintzaras, E., Voulgarelis, M., Moutsopoulos, H. M. (2005). The Risk of Lymphoma Development in Autoimmune Diseases: A Meta-analysis. Arch Intern Med 165: 2337-2344 [Abstract] [Full Text]  
• Douglas, K. M. J., Raza, K., Stevens, R., Erb, N., Jones, E. L., Kitas, G. D. (2005). Bronchial MALT lymphoma in longstanding rheumatoid arthritis. Rheumatology (Oxford) 44: 687-689 [Full Text]  
• Feng, W.-h., Cohen, J. I., Fischer, S., Li, L., Sneller, M., Goldbach-Mansky, R., Raab-Traub, N., Delecluse, H.-J., Kenney, S. C. (2004). Reactivation of Latent Epstein-Barr Virus by Methotrexate: A Potential Contributor to Methotrexate-Associated Lymphomas. JNCI J Natl Cancer Inst 96: 1691-1702 [Abstract] [Full Text]  
• Gelfand, J. M., Berlin, J., Van Voorhees, A., Margolis, D. J. (2003). Lymphoma Rates Are Low but Increased in Patients With Psoriasis: Results From a Population-Based Cohort Study in the United Kingdom. Arch Dermatol 139: 1425-1429 [Abstract] [Full Text]  
• Ebeo, C. T., Girish, M. R., Byrd, R. P., Roy, T. M., Mehta, J. B. (2003). Methotrexate-Induced Pulmonary Lymphoma. Chest 123: 2150-2153 [Abstract] [Full Text]  
• Callen, J. P. (2002). When and How Should the Patient With Dermatomyositis or Amyopathic Dermatomyositis Be Assessed for Possible Cancer?. Arch Dermatol 138: 969-971 [Full Text]  
• Mariette, X., Cazals-Hatem, D., Warszawki, J., Liote, F., Balandraud, N., Sibilia, J. (2002). Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99: 3909-3915 [Abstract] [Full Text]  
• Farrell, R J, Ang, Y, Kileen, P, O'Briain, D S, Kelleher, D, Keeling, P W N, Weir, D G (2000). Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47: 514-519 [Abstract] [Full Text]  
• Greiner, T., Armitage, J. O., Gross, T. G. (2000). Atypical Lymphoproliferative Diseases. ASH Education Book 2000: 133-146 [Abstract] [Full Text]  
• Munro, R, Porter, D R, Sturrock, R D (1998). Lymphadenopathy in a patient with systemic onset juvenile chronic arthritis. Ann Rheum Dis 57: 513-517 [Full Text]  
• Bologna, C., Picot, M.-C., Jorgensen, C., Viu, P., Verdier, R., Sany, J. (1997). Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Ann Rheum Dis 56: 97-102 [Abstract] [Full Text]  
• Schlesinger, N., Huppert, A., Hoch, S., Malleson, P., Steinberg, A. D., Rosh, J. R., Birnbaum, A. H., van de Rijn, M., Kamel, O. W., Storb, R., Thomas, E. D., Tugwell, P., Yocum, D., Pincus, T., Wells, G. (1995). Cyclosporine and Methotrexate for Severe Rheumatoid Arthritis. NEJM 333: 1567-1569 [Full Text]  
• (1995). Methotrexate for rheumatoid arthritis. DTB 33: 17-19 [Abstract] [Full Text]  
• Diehl, V., Tesch, H. (1995). Hodgkin's Disease -- Environmental or Genetic?. NEJM 332: 461-463 [Full Text]  
• Weinblatt, M. E. (1995). Methotrexate for Chronic Diseases in Adults. NEJM 332: 330-331 [Full Text]  
• Ritter, J. H., Wick, M. R. (1994). Posttransplant Lymphoproliferative Disorders: Immunohistologic Differential Diagnosis With Severe Allograft Rejection. INT J SURG PATHOL 2: 105-115 [Abstract]  
• Cash, J. M., Klippel, J. H. (1994). Second-Line Drug Therapy for Rheumatoid Arthritis. NEJM 330: 1368-1375 [Full Text]  
• Shiroky, J. B., Newkirk, M. M., Kamel, O. W., van de Rijn, M., Warnke, R. A., Dorfman, R. F. (1993). Reversible Lymphomas. NEJM 329: 1657-1658 [Full Text]